DOCSLIB.ORG

Acquisita Experimental Epidermolysis Bullosa Activation Is Critical for Blister Induction in the Alternative Pathway of Compleme

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acquisita Experimental Epidermolysis Bullosa Activation Is Critical for Blister Induction in the Alternative Pathway of Compleme The Journal of Immunology The Alternative Pathway of Complement Activation Is Critical for Blister Induction in Experimental Epidermolysis Bullosa Acquisita1 Sidonia Mihai,* Mircea T. Chiriac,* Kazue Takahashi,† Joshua M. Thurman,‡§ V. Michael Holers,‡§ Detlef Zillikens,* Marina Botto,¶ and Cassian Sitaru2* Epidermolysis bullosa acquisita is a subepidermal blistering disease associated with tissue-bound and circulating autoanti- bodies against type VII collagen, a major constituent of the dermal-epidermal junction. The passive transfer of Abs against type VII collagen into mice induces a subepidermal blistering disease dependent upon activation of terminal complement components. To further dissect the role of the different complement activation pathways in this model, we injected C1q- deficient, mannan-binding lectin-deficient, and factor B-deficient mice with rabbit Abs against murine type VII collagen. The development and evolution of blistering had a similar pattern in mannan-binding lectin-deficient and control mice and was initially only marginally less extensive in C1q-deficient mice compared with controls. Importantly, factor B-deficient mice developed a delayed and significantly less severe blistering disease compared with factor B-sufficient mice. A significantly lower neutrophilic infiltration was observed in factor B-deficient mice compared with controls and local reconstitution with granulocytes restored the blistering disease in factor B-deficient mice. Our study provides the first direct evidence for the involvement of the alternative pathway in an autoantibody-induced blistering disease and should facilitate the development of new therapeutic strategies for epidermolysis bullosa acquisita and related autoimmune diseases. The Journal of Immu- nology, 2007, 178: 6514–6521. pidermolysis bullosa acquisita (EBA),3 a severe chronic with recombinant autologous type VII collagen induces an au- subepidermal blistering disease of skin and mucous toimmune response to this protein, resulting in a blistering phe- E membranes, is characterized by tissue-bound and cir- notype closely resembling human EBA (11). culating IgG Abs to the dermal-epidermal junction (1). Patients’ Autoantibodies against type VII collagen are able to activate the serum autoantibodies bind to the 290-kDa type VII collagen, the complement system in vivo and in vitro. In the skin of EBA pa- major component of anchoring fibrils (2, 3). Epitopes recog- tients, deposition of different complement components, including nized by the majority of EBA sera were mapped to the non- C3, C5b, and membrane attack complex, are found with an inci- collagenous 1 domain of type VII collagen (4–6). The patho- dence ranging from ϳ40 to 100% (12–14). In addition, deposition genic relevance of Abs against type VII collagen is supported of C3 at the dermal-epidermal junction of murine skin is a constant by compelling evidence: 1) EBA autoantibodies were shown to feature in different passive transfer mouse models of EBA (9, 10) recruit and activate leukocytes ex vivo, resulting in dermal- and in experimental EBA induced by immunization of mice with epidermal separation in cryosections of human skin (7, 8). 2) autologous type VII collagen (11). These observations suggested Abs against type VII collagen induce subepidermal blisters that the complement system is involved in the autoimmune tissue when passively transferred into mice (9, 10). 3) Immunization injury in EBA. Indeed, this hypothesis was confirmed by our re- cent studies showing that C5-deficient mice are resistant to blister *Department of Dermatology, University of Lu¨beck, Lu¨beck, Germany; †Department induction by passive transfer of Abs against type VII collagen (9). of Pediatrics, Laboratory of Developmental Immunology, Massachusetts General The initiators and processes that result in complement activation ‡ Hospital, Harvard Medical School, Boston, MA 02115; Department of Medicine and can be assigned to three different pathways: classical, alternative, §Department of Immunology, University of Colorado Health Sciences Center, Den- ver, CO 80218; and ¶Rheumatology Section, Imperial College School of Medicine, and lectin. The classical pathway is activated primarily by Ag-Ab London, United Kingdom complexes binding to C1q (15). The lectin pathway is initiated by Received for publication December 19, 2006. Accepted for publication March ficolins and mannan-binding lectin (MBL) (16). The alternative 2, 2007. pathway is continuously activated by factor B through a process The costs of publication of this article were defrayed in part by the payment of page called “tickover” of C3 and requires active control mechanisms to charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. prevent autologous injury (17). The relevance of the different com- 1 This work was supported by Grants Zi 439/6-2 and SI 1281/1-1 from the Deutsche plement components and pathways of the complement cascade in Forschungsgemeinschaft (to C.S. and D.Z.) and National Institutes of Health Grants experimental EBA, which could represent targets for treatment, R01 AI-31105 (to V.M.H.) and K08 DK64790 (to J.M.T.). have remained unknown. 2 Address correspondence and reprint requests to Dr. Cassian Sitaru, Department of Dermatology, University of Lu¨beck, Ratzeburger Allee 160, Lu¨beck, Germany. In the present study, we examined the relative contribution of E-mail address: [email protected] the different complement activation pathways for blister formation 3 Abbreviations used in this paper: EBA, epidermolysis bullosa acquisita; IF, immu- in experimental EBA. Our findings provide the first direct evidence nofluorescence; Bf, complement factor B; MBL, mannan-binding lectin; MPO, my- for the involvement of the alternative pathway in an autoantibody- eloperoxidase; CR, complement receptor; WT, wild type. induced blistering disease and a conceptual framework for devel- Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/$2.00 oping rational therapeutic strategies for EBA and related diseases. www.jimmunol.org The Journal of Immunology 6515 FIGURE 1. C1q-deficient mice are susceptible to the induction of subepi- dermal blisters by Abs specific to type VII collagen. Skin lesions, including blisters and erosions covered by crusts on the ear and front leg, and alopecia of the snout and around the eyes devel- oped in both WT (a) and C1qaϪ/Ϫ mice (b) that received a total dose of 45 mg of rabbit IgG against type VII collagen (day 12). c, A C1qaϪ/Ϫ mouse receiv- ing the same amount of control rabbit IgG did not develop skin lesions. IF mi- croscopy analysis of perilesional skin revealed deposition of rabbit IgG at the dermal-epidermal junction of both WT (d) and C1qaϪ/Ϫ (e) mice injected with Abs against type VII collagen, but not in the C1qaϪ/Ϫ (f) mouse treated with control rabbit IgG. Deposits of mouse C3 along the dermal-epidermal junc- tion were strong in the skin of WT (g) and weak in the skin of C1qaϪ/Ϫ (h) mice injected with Abs against type VII collagen and absent in the C1qaϪ/Ϫ mouse (i) treated with control rabbit IgG. Staining for murine C5 revealed similar deposits in the skin of the WT (j) and of the C1qaϪ/Ϫ (k) mice treated with Abs against type VII collagen, but was absent in the C1qaϪ/Ϫ (l) mouse injected with control rabbit IgG. Histological analysis of lesional skin revealed extensive dermal-epidermal separation and a neutrophil-rich inflam- matory infiltrate in both WT (m) and C1qaϪ/Ϫ (n) mice injected with Abs against type VII collagen. o, Normal histological appearance in the skin of the C1qaϪ/Ϫ mouse injected with con- trol rabbit IgG. Materials and Methods as follows: 0, no lesions; 1, Ͻ10 lesions or Ͻ1% of the skin surface; 2, Ͼ Mice 10 lesions or 1–5% of the skin surface; 3, 5–10%; 4, 10–20%; and 5, Ͼ20% involvement of the skin surface. Biopsies of lesional and perile- C1qaϪ/Ϫ and BfϪ/Ϫ mice, backcrossed to BALB/c mice (for 10 and 7 sional skin were obtained 2 days after the last injection of IgG and prepared generations, respectively), and MBL-null mice backcrossed to C57BL/6J for examination by histopathology and IF microscopy as described previ- mice (for 7 generations), were previously described (18–21). Age- and ously (9, 11). Tissue-bound murine C5 was detected by incubation of the sex-matched BALB/c and C57BL/6J mice were obtained from Charles frozen sections prepared from tissue biopsies with a mAb specific to mu- River. All injections and bleedings were performed on mice narcotized by rine C5 (BB5.1) (22) and, finally, with a FITC-labeled Ab specific to inhalation of isoflurane or i.p. administration of a mixture of ketamine (100 mouse IgG (DakoCytomation). The staining intensity of immunoreactants ␮g/g) and xylazine (15 ␮g/g). The experiments were approved by the local in the skin of immunized mice was assessed semiquantitatively using a authorities of the Animal Care and Use Committee (reference number: score comprising 0, for no staining; 1, faint staining; 2, medium; and 3, 6/g/04) and performed by certified personnel. intense staining (11). Neutrophil infiltration of murine skin was assayed as described previ- Affinity purification of Abs ously (23), with minor modifications. Briefly, in both clinically diseased and not diseased mice, the left ear was removed after killing the mice and Rabbits were immunized with recombinant forms of murine type VII col- skin samples (ϳ10 ϫ 5 mm in size) were extracted by homogenization in lagen as described elsewhere (9). IgG from immune and preimmune rabbit a buffer containing 0.1 M Tris-Cl (pH 7.6), 0.15 M NaCl, and 0.5% hexa- sera was purified by affinity chromatography using protein G affinity as decyl trimethylammonium bromide (Sigma-Aldrich). Myeloperoxidase previously reported (9). Reactivity of IgG fractions was analyzed by im- (MPO) activity in the supernatant fraction was measured by the change in munofluorescence (IF) microscopy on murine skin.
Load more

Recommended publications
  • Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002
    Department of Health & Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002 CHANGE REQUEST 2149 HEADER SECTION NUMBERS PAGES TO INSERT PAGES TO DELETE Table of Contents 2 1 45-30 - 45-31 2 2 NEW/REVISED MATERIAL--EFFECTIVE DATE: October 1, 2002 IMPLEMENTATION DATE: October 1, 2002 Section 45-31, Intravenous Immune Globulin’s (IVIg) for the Treatment of Autoimmune Mucocutaneous Blistering Diseases, is added to provide limited coverage for the use of IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita. Use J1563 to bill for IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid, and (5) Epidermolysis Bullosa Acquisita. This revision to the Coverage Issues Manual is a national coverage decision (NCD). The NCDs are binding on all Medicare carriers, intermediaries, peer review organizations, health maintenance organizations, competitive medical plans, and health care prepayment plans. Under 42 CFR 422.256(b), an NCD that expands coverage is also binding on a Medicare+Choice Organization. In addition, an administrative law judge may not review an NCD. (See §1869(f)(1)(A)(i) of the Social Security Act.) These instructions should be implemented within your current operating budget. DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted. CMS-Pub.
    [Show full text]
  • Bullous Pemphigoid/Pemphigus and Administration of the Pfizer/Biontech Vaccine (Comirnaty®). Introduction the Pfizer/Bionte
    Bullous Pemphigoid/Pemphigus and administration of the Pfizer/BioNTech vaccine (Comirnaty®). Introduction The Pfizer/BioNTech vaccine (Comirnaty®) is a COVID-19-mRNA-vaccine (nucleoside modified). It is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. [1] The nucleoside-modified messenger RNA in Comirnaty® is formulated in lipid nanoparticles, which enable delivery of the nonreplicating RNA into host cells to direct transient expression of the SARS-CoV-2 S antigen. The mRNA codes for membrane-anchored, full-length Spike glycoprotein with two point mutations within the central helix. [1] Comirnaty® has been registered in Europe since December 21st, 2020. Bullous skin diseases are a group of dermatoses characterized by blisters and bullae in the skin and mucous membranes. The most common are pemphigus and bullous pemphigoid (BP). Pemphigus and bullous pemphigoid are autoantibody-mediated blistering skin diseases. In pemphigus, keratinocytes in epidermis and mucous membranes lose cell-cell adhesion, and in pemphigoid, the basal keratinocytes lose adhesion to the basement membrane. Bullous pemphigoid is a more common disease than pemphigus [2]. Bullous pemphigoid is the most common heterogeneous subepidermal autoimmune blistering disease (incidence 7 per million person year) [3,4], with an increasing prevalence after the age of 70, although it can also occur in the younger. It is characterized by auto-antibodies against different structural proteins of the hemidesmosomes in the epidermal basement membrane zone (EBMZ). Bullous pemphigoid typically causes severe pruritus with predominantly cutaneous lesions consisting of tense (fluid filled) bullae, erythema, and urticarial plaques.
    [Show full text]
  • Dermatitis Herpetiformis
    Dermatitis herpetiformis Authors: Professors Paolo Fabbri 1 and Marzia Caproni Creation date: November 2003 Update: February 2005 Scientific editor: Professor Benvenuto Giannotti 1II Clinica Dermatologica, Dipartimento di Scienze Dermatologiche, Università degli Studi di Firenze, Via degli Alfani 37, 50121, Firenze, Italy. [email protected] Summary Keywords Disease name and synonyms Definition Prevalence Clinical manifestations Differential diagnosis Etiopathogenesis Management – treatment Diagnostic criteria – methods References Summary Dermatitis herpetiformis (DH) is a subepidermal bullous disease characterized by chronic recurrence of itchy, erythematous papules, urticarial wheals and grouped vesicles that appear symmetrically on the extensor surfaces, buttocks and back. Children and young adults are mostly affected. Prevalence is estimated to be about 10 to 39 cases/100,000/year, with incidence ranging from 0,9 (Italy) to 2,6 (Northern Ireland) new cases/100,000/year. The disease is the cutaneous expression of a gluten-sensitive enteropathy identifiable with celiac disease. The clinical and histological pictures of both entities are quite similar. Granular IgA deposits at the dermo-epidermal junction, neutrophils and eosinophils together with activated CD4+ Th2 lymphocytes are supposed to represent the main immune mechanisms that co- operate in the pathogenesis of the disease. A strict gluten withdrawal from diet represents the basis for treatment. Keywords autoimmune bullous diseases, celiac disease, tissue transglutaminase, anti-endomysium antibodies, anti- tissue transglutaminase antibodies, gluten sensitivity, dapsone. deposits at the dermal papillae represent the immunological marker of the disease, that is strictly associated with a gluten-sensitive Disease name and synonyms enteropathy (GSE), indistinguishable from celiac - Dermatitis herpetiformis (DH), disease (CD). 1 - Duhring-Brocq disease, - Duhring’s dermatitis.
    [Show full text]
  • Transcription
    Amethyst: Welcome, everyone! This call is now being recorded. I would like to thank you for ​ being on the call this evening and to our Sponsors Genentech, Principia Biopharma, Argenx, and Cabaletta Bio for making today’s call possible. Today’s topic is Peer Support to answer your question about living with pemphigus and pemphigoid with the IPPF’s Peer Health Coaches. So before we begin, I want to take a quick poll to see how many of you have connected with an IPPF Peer Health Coach (either by phone or email)? While you are answering the poll let me introduce you to the IPPF Peer Health coaches: Marc Yale is the Executive Director of the IPPF and also works as a PHC. Marc was diagnosed ​ in 2007 with Cicatricial Pemphigoid, a rare autoimmune blistering skin disease. Like others with a rare disease, he experienced delays in diagnosis and difficulty finding a knowledgeable physician. Eventually, Marc lost his vision from the disease. This inspired him to help others with the disease. In 2008, he joined the IPPF as a Peer Health Coach. Becky Strong is the Outreach Director of the International Pemphigus & Pemphigoid ​ Foundation and also works as a PHC. She was diagnosed with pemphigus vulgaris in 2010 after a 17-month journey that included seeing six different doctors from various specialties. She continues to use this experience to shine a light on the average pemphigus and pemphigoid patient experience of delayed diagnosis and bring attention to how healthcare professionals can change the patient experience. Mei Ling Moore was diagnosed with Pemphigus Vulgaris in February of 2002.
    [Show full text]
  • Oral Signs of Systemic Disease CDA 2015 Lecture Notes
    2015-08-28 Oral Signs of Oral Signs of Systemic Disease Systemic Disease Why do you need to know? ! AHA! I diagnosed your systemic disease – less likely ! Helping your patients with known Karen Burgess, DDS, MSc, FRCDC systemic diseases - more likely Oral Pathology and Oral Medicine, Faculty of Dentistry, University of Toronto Department of Dentistry, Princess Margaret Hospital Department of Dentistry, Mt Sinai Hospital 2015-08-29 2015-08-29 2015-08-29 2015-08-29 2015-08-29 2015-08-29 Normal or Abnormal? Clinical description ! Type of abnormality (shape) ! The hardest part of oral pathology ! Number ! Colour ! Consistency ! Size - measure accurately ! Surface texture ! Location 2015-08-29 2015-08-29 2015-08-29 1 2015-08-28 Vocabulary Clinical description ! Ulcer ! Type of abnormality (shape) ! Vesicle/Bulla ! Number ! Macule ! Colour ! Patch ! Consistency ! Plaque ! Size - measure accurately ! Polyp- sessile or pedunculated ! Surface texture ! Location 2015-08-29 2015-08-29 2015-08-29 Description 2015-08-29 2015-08-29 2015-08-29 Differential Diagnosis Differential Diagnosis Differential Diagnosis ! Erythema multiforme ! Mucous membrane pemphigoid ! Primary herpes ! Erythema multiforme –"Any genital or eye lesions –"How long has it been present? ! Mucous membrane pemphigoid –"Any blisters? –"Any skin lesions? ! Pemphigus vulgaris ! Pemphigus vulgaris –"any skin lesions? ! Lichen planus ! Primary herpes –"Any blisters? –"How long has it been present? ! Lichen planus What information will help you narrow down –"Any other symptoms – malaise,
    [Show full text]
  • Epidermolysis Bullosa Acquisita Associated with Relapsing Polychondritis: an Association with Eosinophilia? Christine A
    Epidermolysis Bullosa Acquisita Associated with Relapsing Polychondritis: An Association with Eosinophilia? Christine A. Papa, DO, Danville, Pennsylvania Michele S. Maroon, MD, Danville, Pennsylvania William B. Tyler, MD, Danville, Pennsylvania Epidermolysis bullosa acquisita is a blistering dis- order that has been associated with other autoim- mune diseases. It has not previously been associ- ated with relapsing polychondritis (RPC). RPC is an autoimmune disorder that frequently displays peripheral eosinophilia. The eosinophil has been implicated in mediation of tissue damage and bul- lae formation. RPC should be added to the list of diseases seen in association with EBA. pidermolysis bullosa acquisita (EBA) is a rare, usually chronic blistering disorder that has been associated with systemic diseases in which au- E 1 toimmune pathogenesis has been implicated. It has not been described in association with relapsing polychon- dritis (RPC). Three clinical forms of EBA exist.2 The classic presentation has noninflammatory acral bullae associated with trauma that heal with scarring and milia. The bullous pemphigoid-like presentation has widespread inflammatory bullae surrounded by urticar- ial plaques involving the trunk; these heal without scar- FIGURE 1. Sharply marginated erythema and edema of ring or milia. The cicatricial pemphigoid-like presen- cartilaginous ear. tation has predominantly mucosal involvement. EBA is often refractory to treatment. ly (Figure 1) and less intensely over the cartilaginous alae. Her nonspecific eruption rapidly evolved to tense Case Report bullae on edematous, erythematous urticarial bases over A previously healthy 75-year-old white woman was a 3-day period (Figure 2). There was no mucosal hospitalized for a 3-week history of generalized weak- involvement.
    [Show full text]
  • Radiation-Induced Pemphigus Or Pemphigoid Disease in 3 Patients with Distinct Underlying Malignancies
    Radiation-Induced Pemphigus or Pemphigoid Disease in 3 Patients With Distinct Underlying Malignancies Wonwoo Shon, DO; David A. Wada, MD; Amer N. Kalaaji, MD PRACTICE POINTS • The use of radiation therapy is increasing because of its therapeutic benefit, especially in advanced-stage cancer patients. • Although there is a wide range of adverse effects associated with radiation therapy, pemphigus or pemphigoid disease is rare and needs to be distinguished from other skin diseases or even recurrent underlying cancer. • The precise mechanism of radiation-induced pemphigus or pemphigoid disease is unknown, but clinicians should be alert to this potentially serious complication, and all cutaneous eruptions developing during and after radiation therapy should be evaluated with routine histologic examination in conjunction with direct immunofluorescence, serum for indirect immunofluorescence, and enzyme-linked immunosorbent assay. The cutaneous lesions of radiation-induced pem- eruption is unknown, clinicians should be alert for phigus or pemphigoid disease may resemble this potentially serious complication and evaluate other skin diseases, including recurrent underly- all cutaneous eruptions developing during and ing cancer. We performed a computerized search after radiotherapy. of Mayo Clinic (Rochester, Minnesota) archives Cutis. 2016;97:219-222. and identified 3 cases of pemphigus or pemphi- goid disease that occurredCUTIS after radiation therapy Do not copy for breast, cervical, and metastatic malignancies, number of adverse cutaneous effects may respectively. In 2 of these patients, the disease result from radiation therapy, including was initially confined to the irradiated field but A radiodermatitis, alopecia, and radiation- subsequently disseminated to other parts of the induced neoplasms. Radiation therapy rarely induces patients’ bodies, including mucosal surfaces.
    [Show full text]
  • A Rare Case of a Subepidermal Bullous Disorder in a Child
    Pediatric dermatology Series Editor: Camila K. Janniger, MD Bullous Systemic Lupus Erythematosus With Lupus Nephritis: A Rare Case of a Subepidermal Bullous Disorder in a Child Shital Poojary, MD, FCPS, DNB; Sama Rais, MBBS Bullous systemic lupus erythematosus (BSLE) characterized by a distinct constellation of clini- is a rare subset of systemic lupus erythemato- cal, histologic, and immunologic features.1 Bullous sus (SLE) with bullous lesions in a case fulfilling the systemic lupus erythematosus is extremely rare in American Rheumatism Association (Atlanta) crite- children.2 We report a case of a 9-year-old Indian girl ria, histologically characterized by a neutrophil- with BSLE and lupus nephritis; we review the clinical predominant infiltrate in theCUTIS upper dermis with features as well as the etiopathogenesis of BSLE. immunoglobulin (IgG, IgA, IgM) and C3 deposi- tion at the basement membrane zone (BMZ). It Case Report often is associated with autoimmunity to type VII A 9-year-old girl presented with a blistering eruption collagen (NC1 [noncollagenous domain 1] over her chest, back, arms, and neck of 15 days’ dura- domain), although occasionally other antigens tion; swelling around the eyes and feet of 15 days’ such as laminin 5, laminin 6, and BP230 (bullous duration; and a low-grade fever of 2 months’ dura- pemphigoidDo antigen) have beenNot described. Bullous tion. PhysicalCopy examination revealed multiple tense systemic lupus erythematosus is extremely rare vesicles and bullae overlying urticarial plaques on in children. the neck, chest (Figure 1), back, and arms with no We report here a case of a 9-year-old girl with mucous membrane involvement.
    [Show full text]
  • Management of Oral Soft Tissue Conditions and the Use of Medications
    Management of Oral Soft Tissue Conditions and the Use of Medications 29 August 2017 Mike Brennan DDS, MHS Department of Oral Medicine Carolinas Medical Center Charlotte, NC Objectives • Differential diagnosis of soft tissue conditions • Describe more common soft tissue conditions • Diagnosis of soft tissue conditions • Management strategies of mucosal lesions • Treatment • Prevention Differential Diagnosis-NIRDS • Neoplastic • Infectious • Reactive • Developmental • Systemic NEOPLASTIC Leukoplakia- White • Clinical diagnosis only • Histologically: hyperplasia, mild, moderate, or severe dysplasia, carcinoma in-situ, invasive carcinoma • Thin leukoplakia: seldom malignant change • Thick leukoplakia: 1-7% malignant change • Granular or verruciform: 4-15% malignant change • Erythroleukoplakia: 28% malignant change Neoplastic: Red Lesions •SCCA Diagnosis: Incisional vs. Excisional Biopsies Dysplasia Management – Medical • Systematic Review: 9 studies met criteria for low bias in prior review • Three studies were reviewed based adequate study quality. • topical bleomycin • systemic retinoids • systemic lycopene • No therapeutic recommendations for bleomycin and cis-retinoic acid • Lycopene (4 and 8 mg) may have some efficacy in patients with risk factors similar to those found in a subcontinental Indian population, for the short- term resolution of oral epithelial dysplasia Dysplasia Management – Surgical • Lack RCTs that would allow to assess the effectiveness of surgical treatment, including lasers • In non-RCTs the effectiveness of various
    [Show full text]
  • Bullous Pemphigoid
    JAMA DERMATOLOGY PATIENT PAGE Bullous Pemphigoid ullous pemphigoid is an autoimmune disease, Progression and appearance of bullous pemphigoid which means that the cells in the body that in dark- and light-skinned individuals normally fight infection attack the body EARLY HEALING LATE instead. The body’s immune system is confused Band makes an antibody (type of protein used to fight Blisters Erosions Increased pigmentation infection) that targets a part of the skin that normally (bullae) (broken blisters) holds it together. The attack on the skin causes blisters (firm, fluid-filled bubbles on the skin) to form. This disease most often involves only the skin, but the eyes, mouth, and genitals also can be affected. In most cases, the disease develops on its own, but certain medications also can cause bullous pemphigoid to develop. Bullous pemphigoid commonly affects people older than 60 years but can occur in younger people. Once someone is diagnosed as having this disease, they can have it for many years. Treatment helps to control the disease, but there is no permanent cure. SYMPTOMS Hivelike rash Redness Severe itching and blisters occur in almost all patients. Erosions Early in the course of the disease, some patients may not have blisters but instead have only a rash that looks similar to hives. These hivelike spots can be all over the body; Blisters many times, when blisters appear, they will appear on top of this rash. Blisters will sometimes break, and the exposed skin can be raw and painful. Scars usually do not develop, and the skin can return to normal, although darker spots may remain after the blisters go away.
    [Show full text]
  • Blistering Skin Conditions
    THEME WEIRD SKIN STUFF Belinda Welsh MBBS, MMed, FACD, is consultant dermatologist, St Vincent's Hospital, Melbourne and Sunbury Dermatology and Skin Cancer Clinic, Sunbury, Victoria. [email protected] Blistering skin conditions Blistering of the skin is a reaction pattern to a diverse Background group of aetiologic triggers and can be classified as either: Blistering of the skin can be due to a number of diverse • immunobullous (Table 1), or aetiologies. Pattern and distribution of blisters can be helpful in • nonimmunobullous (Table 2). diagnosis but usually biopsy is required for histopathology and immunofluoresence to make an accurate diagnosis. Separation of the skin layers leading to acquired blistering can occur due to loss of cohesion of cells: Objective • within the epidermis (Figure 1) This article outlines the clinical and pathological features of • between the epidermis and dermis (basement membrane blistering skin conditions with a particular focus on bullous zone) (Figure 2), or impetigo, dermatitis herpetiformis, bullous pemphigoid and • in the uppermost layers of the dermis. porphyria cutanea tarda. Discussion This distinction forms the histologic basis of diagnosing many of the Infections, contact reactions and drug eruptions should different blistering diseases. Clinical patterns may also be helpful and always be considered. Occasionally blistering may represent are listed in Table 3. Important features include: a cutaneous manifestation of a metabolic disease such as • location of the blisters (Figure 3, 4) porphyria. Although rare, it is important to be aware of the autoimmune group of blistering diseases, as if unrecognised and • the presence or absence of mucosal involvement, and untreated, they can lead to significant morbidity and mortality.
    [Show full text]
  • A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy
    antibodies Review A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy Payal M. Patel 1,2 , Virginia A. Jones 1 , Christy T. Behnam 1, Giovanni Di Zenzo 3 and Kyle T. Amber 2,4,* 1 Department of Dermatology, University of Illinois at Chicago College of Medicine, Chicago, IL 60612, USA; [email protected] (P.M.P.); [email protected] (V.A.J.); [email protected] (C.T.B.) 2 Rush University Medical Center, Division of Dermatology, Department of Otorhinolaryngology—Head and Neck Surgery, Rush University, Chicago, IL 60612, USA 3 Laboratory of Molecular and Cell Biology, IDI-IRCCS, 00167 Rome, Italy; [email protected] 4 Rush University Medical Center, Department of Internal Medicine, Rush University, Chicago, IL 60612, USA * Correspondence: [email protected] Abstract: Gene therapy serves as a promising therapy in the pipeline for treatment of epidermolysis bullosa (EB). However, with great promise, the risk of autoimmunity must be considered. While EB is a group of inherited blistering disorders caused by mutations in various skin proteins, autoimmune blistering diseases (AIBD) have a similar clinical phenotype and are caused by autoantibodies targeting skin antigens. Often, AIBD and EB have the same protein targeted through antibody or mutation, respectively. Moreover, EB patients are also reported to carry anti-skin antibodies of questionable pathogenicity. It has been speculated that activation of autoimmunity is both a consequence and cause of further skin deterioration in EB due to a state of chronic inflammation. Citation: Patel, P.M.; Jones, V.A.; Behnam, C.T.; Zenzo, G.D.; Amber, Herein, we review the factors that facilitate the initiation of autoimmune and inflammatory responses K.T.
    [Show full text]